超声引导下透明质酸注射与皮质类固醇注射治疗莫顿神经瘤的比较
本研究将45例莫顿神经瘤患者随机分为透明质酸组和皮质类固醇组,每组22例(24足),分别接受三次超声引导下注射(每周一次)。两组在12个月时VAS和AOFAS评分均显著改善,皮质类固醇组在1、3、6个月时疼痛和功能改善显著优于透明质酸组,但12个月时无显著差异;透明质酸组无并发症,皮质类固醇组6例(25.0%)出现局部皮肤变色。
要点
- 皮质类固醇组在1、3、6个月时VAS降低和AOFAS评分升高均显著优于透明质酸组,12个月时无显著差异。
- 透明质酸组无并发症,皮质类固醇组6例(25.0%)出现注射部位皮肤变色。
- 作者认为皮质类固醇注射应作为主要选择,透明质酸仅可用于有皮质类固醇禁忌证的患者。
核心结论
- 超声引导下皮质类固醇注射在多个时间点的功能和疼痛结局上统计学显著优于透明质酸注射。
- 作者认为皮质类固醇注射应被视为这些患者的主要选择,透明质酸注射的唯一指征可能是存在皮质类固醇禁忌证的患者。
研究设计与样本
- 随机对照试验,共评估91例患者,最终纳入45例并随机分为两组,每组22例(24足),1例失访。
- 透明质酸组接受三次超声引导下透明质酸(Osteonil Plus)注射(每周一次),皮质类固醇组接受三次超声引导下曲安奈德(Triancil)注射(每周一次)。
- 主要结局指标为疼痛视觉模拟评分(VAS),次要结局指标包括美国足踝骨科协会(AOFAS)评分和并发症。
- 评估时间点为治疗前及治疗后1、3、6、12个月。
主要发现
- 两组在12个月时VAS和AOFAS评分均较治疗前显著改善(p < 0.05)。
- 皮质类固醇组在1、3、6个月时VAS降低和AOFAS评分升高均显著优于透明质酸组,12个月时无显著差异。
- 透明质酸组无并发症;皮质类固醇组6例(6足)(25.0%)出现轻微局部并发症,均为注射部位皮肤变色。
- 无患者后续接受神经瘤切除术。
临床怎么用
- 作者认为皮质类固醇注射应被视为莫顿神经瘤患者的主要治疗选择。
- 作者认为透明质酸注射的唯一指征可能是存在皮质类固醇禁忌证的患者。
局限性
- 原文提到皮质类固醇组的轻微并发症可能源于每周三次注射相对较高剂量的皮质类固醇。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: A local injection may be used as an early option in the treatment of Morton's neuroma, and can be performed using various medications. The aim of this study was to compare the effects of injections of hyaluronic acid compared with corticosteroid in the treatment of this condition. METHODS: A total of 91 patients were assessed for this trial, of whom 45 were subsequently included and randomized into two groups. One patient was lost to follow-up, leaving 22 patients (24 feet) in each group. The patients in the hyaluronic acid group were treated with three ultrasound-guided injections (one per week) of hyaluronic acid (Osteonil Plus). Those in the corticosteroid group were treated with three ultrasound-guided injections (also one per week) of triamcinolone (Triancil). The patients were evaluated before treatment and at one, three, six, and 12 months after treatment. The primary outcome measure was the visual analogue scale for pain (VAS). Secondary outcome measures included the American Orthopaedic Foot and Ankle Society (AOFAS) score, and complications. RESULTS: Both groups showed significant improvement in VAS and AOFAS scores (p < 0.05) after 12 months. The corticosteroid group had a significantly greater reduction in VAS and increase in AOFAS scores compared with the hyaluronic acid group, at one, three, and six months, but with no significant difference at 12 months. There were no complications in the hyaluronic acid group. There were minor local complications in six patients (six feet) (25.0%) in the corticosteroid group, all with discolouration of the skin at the site of the injection. These minor complications might have been due to the three weekly injections of a relatively high dose of corticosteroid. No patient subsequently underwent excision of the neuroma. CONCLUSION: An ultrasound-guided corticosteroid injection showed statistically significantly better functional and pain outcomes than an ultrasound-guided injection of hyaluronic acid for the treatment of a Morton's neuroma at many timepoints. Thus, a corticosteroid injection should be regarded as a primary option in the treatment of these patients, and the only indication for an injection of hyaluronic acid might be in patients in whom corticosteroid is contraindicated.
引用
- Ferreira GF, Lewis TL, Fernandes TD, et al. Ultrasound-guided infiltration with hyaluronic acid compared with corticosteroid for the treatment of Morton's neuroma. Bone Joint J. 2024. PMID: 39348919. doi:10.1302/0301-620X.106B10.BJJ-2024-0342.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。